Title:

Circulating Tumor DNA As A MRD Assessment And Recurrence Risk In Patients Undergoing Curative Intent Resection With Or Without Adjuvant Chemotherapy In Colorectal Cancer: A Meta-analysis

Authors:

Anusha Chidharla^{*1}, Eliot Rapoport^{* 2}, Kriti Agarwal ³, Samragnyi Madala ⁴, Brenda Linares ⁵, Weijing Sun¹, Sakti Chakrabarti ⁶, Anup Kasi ¹

Affiliations:

1. University of Kansas Cancer Center, Kansas City, KS.

2. Montefiore, Albert Einstein College of Medicine, Bronx.

3. Hackensack University Medical Center, Hackensack, NJ.

4. University of Iowa Hospitals and Clinics, Iowa city, Iowa.

5. Kansas University Medical Center, Kansas City, KS.

6. University Hospitals Seidman Cancer Center, Cleveland, OH.

* Contributed equally as first authors.

Abstract:

PURPOSE: Emerging data have suggested that circulating tumor DNA (ctDNA) can be a reliable biomarker for Minimal residual disease (MRD) in CRC patients. Recent studies have shown that the ability to detect MRD using ctDNA assay after curative-intent surgery will change how to assess recurrence risk and patient selection for adjuvant chemotherapy.

METHODS: We performed a meta-analysis of post-operative ctDNA in Stage I-IV (oligometastatic) CRC patients after curative-intent resection. We included 23 studies representing 3,568 patients with evaluable ctDNA in CRC patients post-curative intent surgery. Data were extracted from each study to perform a meta-analysis using RevMan 5.4. software. Subsequent subgroup analysis was performed for stages I-III and oligometastatic stage IV CRC patients.

RESULTS: The pooled hazard ratio (HR) for recurrence-free survival (RFS) in post-surgical ctDNA positive versus negative patients in all stages was 7.27 (95% CI 5.49-9.62) p <0.00001. Subgroup analysis revealed pooled HR of 8.14 (95% CI 5.60-11.82) and 4.83 (95% CI 3.64-6.39) for stage I-III and IV CRC, respectively. The pooled HR for RFS in post-adjuvant chemotherapy ctDNA positive versus negative patients in all stages was 10.59 (95% CI 5.59-20.06) p <0.00001. The subgroup analysis based on the ctDNA method showed a pooled HR of 8.66 (95% CI 6.38-11.75) and 3.76 (95% CI 2.58-5.48) for tumor-informed and tumor-agnostic, respectively.

CONCLUSION: Our analysis emphasizes that post-operative ctDNA is a strong prognostic marker of RFS. Based on our results, ctDNA can be a significant and independent predictor of

RFS. This real-time assessment of treatment benefits using ctDNA can be used as a surrogate endpoint for the development of novel drugs in the adjuvant setting.

Introduction:

Cell-free DNA (cfDNA) are small DNA fragments (160-200 bp) released into the bloodstream during cell death. In healthy adults, cfDNA is primarily released by hematopoietic cells; however, in the setting of cancer, many tumors also release DNA fragments, referred to as circulating tumor DNA (ctDNA), into the systemic circulation. ^{1–3} CtDNA has a short half-life of approximately 2 hours. This property allows it to be used as a dynamic marker for tracking the presence of the tumor. ^{4,5} Although somewhat limited by the delayed turnaround time and cost, there is significant interest in ctDNA. It is a minimally invasive test, which, given its dynamic nature, has high sensitivity and specificity. ^{1,6,7}

Two forms of ctDNA analysis have been developed: tumor-informed techniques and tumoragnostic or tumor-naive techniques. In tumor-informed methods (e.g., signatera and SafeSeqS), first somatic mutations are first identified in tumor tissue, followed by targeted sequencing of plasma DNA using a personalized assay. Tumor-informed assays have better sensitivity and specificity than tumor-agnostic assays where generic gene panels are used (e.g., guardant).^{3,8,9} A significant drawback is the prolonged turnaround time required for personalization. Both methods are currently being evaluated despite cost concerns, hematopoiesis-associated false positives, and reproducibility.

The utility of ctDNA is being explored in numerous contexts, with evidence supporting its role in early cancer detection, monitoring treatment response, and evaluating recurrence and efficacy for multiple forms of cancer. One specific area of interest is its role in assessing minimal residual disease (MRD) and the possibility of its use to guide therapeutic decisions. One hope is that it will be able to guide treatment in the controversial setting of adjuvant chemotherapy (ACT) in stage II and other non or oligometastatic colorectal cancers (CRC). The role of ACT in this setting is poorly defined because of the heterogeneity within disease stages.¹⁰

The benefit of adjuvant 5-FU-based chemotherapy in locally advanced colon cancer has been recognized since the late 1980s. A meta-analysis published by Buyse et al. in 1988 comparing adjuvant 5-FU with surgery alone favored adjuvant chemotherapy with a mortality odds ratio of 0.83 (95% CI 0.70-0.98.¹¹ This was established by North Central Cancer Therapy Group (NCCTG)2 and Intergroup (INT)-00353 trials, which formed the basis for current guideline recommendations to include 5-FU-based adjuvant chemotherapy in stage II/III colon cancer patients. While the guidelines for adjuvant chemotherapy in stage III colon cancer are unambiguous, its use in stage II disease is debatable—especially considering the toxicity associated with chemotherapy regimens with unclear benefits. ^{11,12}Current guidelines recommend 3-6 months of adjuvant chemotherapy after surgery for nonmetastatic colon cancer.¹³ In patients deemed to have high-risk Stage II CRC, surgery is followed by adjuvant chemotherapy. This decision is made based on tumor size as well as pathological and clinical features of the disease, which are relatively poor predictors.¹³ Not all patients require ACT, and it has been challenging to determine what subset does.^{10,11,14,15} Henceforth, there is a need for predictive and prognostic

biomarkers for follow-up detection of early recurrence, thereby enabling appropriate follow-up and therapeutic strategies for early recurrence detection and curative treatment.

Recent advances in technology in ctDNA assay can detect minimal residual disease (MRD) after curative intent surgery. ^{16,17}Using ctDNA to guide the treatment can help avoid the toxic effects of chemotherapy after surgery, especially in patients with a low risk of recurrence. ctDNA has been shown to have a prognostic value and is a good predictor of cancer recurrence in many recent studies. ¹⁸Emerging data have suggested that circulating tumor DNA (ctDNA) can be a reliable biomarker for MRD. This may change how to assess recurrence risk and patient selection for adjuvant chemotherapy. ¹⁹ Therefore, we conducted a systematic review and meta-analysis of studies evaluating the value of ctDNA in the post-surgical and post-ACT periods to predict prognosis and recurrence.

Materials and Methods:

This systematic review and meta-analysis were exempt from institutional review board approval based on Kansas University Medical Center criteria. The study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (<u>PRISMA</u>) recommendations.

A professional librarian searched PubMed/Medline, EMBASE Web of Science, Cochrane Library, and Google from the database inception through June 8, 2022, using Keywords, Medical Subject Heading (MeSH), and EMTREE subject headings used to search for the concepts of colon cancer, ctDNA, survival, and types of studies. The search included full-text articles and conference presentations. The search terms *colorectal neoplasm* AND *circulating tumor DNA* were expanded and used with appropriate MeSH terms. The results were refined according to the study type and outcomes.

Study Eligibility:

Studies were evaluated by at least two independent reviewers (AC, ER, KA), with a third confirming the final inclusion and resolving disagreements (AK). Studies were chosen on the basis of the following criteria: (1) randomized clinical trials or prospective/retrospective cohort studies, (2) patients with stage I-III or oligometastatic stage IV colorectal cancer; (3) studies examining post-operative ctDNA status or post-adjuvant ctDNA status (4) ctDNA data were derived from a panel of mutations rather than single mutations (5) data were available on patient outcomes including disease-free survival, recurrence-free survival, or overall survival (6) the data is not better represented in another entry; (7) both full published manuscripts and conference abstracts were included. Studies beyond the inclusion criteria or those originally published in a language other than English were excluded.

Data Extraction:

Extraction was performed by at least two reviewers (AC, ER, KA), with disputes resolved by discussion with the third. Data were recorded regarding study characteristics, patient demographics, stages studied, ctDNA collection method, the timing of ctDNA collection, and reported Recurrence Free Survival (RFS)/ Recurrence Free Interval (RFI) in both post-surgical and post-adjuvant chemotherapy periods. In addition, data were recorded for individual subgroups such as stages and the study at large when available.

Statistical Analysis:

Data analysis was performed using Review Manager V.5.3 (The Nordic Cochrane Center, Cochrane Collaboration, Copenhagen, Denmark). If the study had more than one outcome, precision was compared to give a more conservative estimate of the HRs and 95% \Box CI. The I² statistic was used to assess the statistical heterogeneity. An I² statistic of >50% was considered significant heterogeneity. Statistical significance was set at p value <0.05. Publication bias was assessed visually using funnel plots. All studies were assessed to be of moderate quality. The pooled HR and 95% \Box CI are represented in forest plots. Each square on the chart area represents an individual study, and the area of each square is equivalent to the weight of the study, which is the inverse of the study variance. The diamond represents summary measures, and the width corresponds to the 95% \Box CI. A random-effects model with inverse variance (DerSimonian and Laird method) was applied.²⁰ Heterogeneity was estimated using the inconsistency index and χ^2 test.

Results:

Our search yielded a total of 668 articles. After screening and final selection, 23 unique studies provided quantitative data on RFS based on the post-operative and post adjuvant ctDNA status. A PRISMA diagram is shown in Figure 1. The characteristics of these studies are summarized in Table 1. Henricksen et al. 2021 and Henricksen et al. 2022 were duplicates but were used for different analyses.^{18,19} Of these studies, seven provided data on the prognostic value of post-adjuvant ctDNA. The studies primarily focused on locally invasive or otherwise nonmetastatic cancers, although eight studied ctDNA in oligometastatic stage IV rectal cancer amenable to curative intent resection. Most studies (17/23) utilized a tumor-informed ctDNA analysis method.




Figure 1: PRISMA flow diagram

Table 1: Characteristics of the studies included in this meta-analysis

| Study | Sta ge of CR C | Colo n vs Rect al canc er or Both | ctDNA Assay | Tumo r Infor med vs Agnos tic/Na ive | Timing of ctDNA Collectio n | Num ber of Patie nts | N ctDN A Positi ve | Adjuv ant Data Availa bility Yes (Y) or No |
|-------|----------------------------|---|----------------|---|---|----------------------------------|--------------------------------|---|
| | | Dom | | ive | | | | NO (N) |

| Ananda ppa et al., 2021 | II- III | CRC | Safe- SeqS | Infor med | NA | 107 | 14 (13%) | |
|---|--------------|------------|-------------------------------|--------------|--------------------|-----|-----------------|---------------|
| Benhai m et al., 2021 | II- III | CRC | Safe- SeqS | Naive | 5 days | 187 | 18 (9%) | |
| Bolhuis et al., 2021 | O M IV | Colo n | QiAa mp | Naive | 38 days average | 23 | 6 (26%) | |
| Chen et al., 2021 | II- III | CRC | SafeSe qS | Infor med | 3-7 days | 240 | 20 (8%) | Availa ble |
| Diehn et al., 2017 | II- III | CRC | QIAa mp | Infor med | 10 days | 145 | 12 (8%) | |
| Gu et al., 2021 | I- III | CRC | AVEN IO | Infor med | 7-10 days | 25 | 4 (16%) | |
| Henriks en et al, 2021 (stages I-III) | I- III | CRC | Signat era, bespok e | Infor med | 2-4 Weeks | 218 | 20 (9%) | |
| Henriks en et al., 2022* | III | CRC | Guard ant | Infor med | 2-4 Weeks | NA | NA | Y |
| Khakoo et al., 2020 | I- III | Rect al | Guard ant | Infor med | 4-12 Weeks | 47 | 3 (6%) | |

| Kotaka et al., 2022 | I- O M IV | CRC | Signat era, bespok e | Infor med | 4 Weeks | 1365 | 115 (8%) | |
|---|--------------------|-----------|-------------------------------|--------------|-------------------------------|------|-----------------|---|
| Li et al., 2022 | III | Colo n | Super- Seq | Infor med | 2-4 Weeks | 151 | 24 (15%) | Y |
| Loupaki s et al., 2021 | O M IV | CRC | Safe- SeqS | Infor med | 8-99 days | 112 | 61 (54%) | |
| McDuff et al., 2021 | II- III | CRC | ddPCR | Infor med | 1-5 Months | 19 | 4 (21%) | |
| Øgaard et al., 2022 | O M IV | CRC | Signat era, bespok e | Naive | 0.9-1.7 Months | 96 | 39 (40%) | Y |
| Overma n et al., 2017 | O M IV | CRC | Genes eq Prime | Naive | Immedia tely post-op | 54 | 24 (44%) | |
| Parikh et al., 2021 | I- O M IV | CRC | TrIMet h | Naive | 4 Weeks | 84 | 17 (20%) | |
| Reinert et al., 2022 | O M IV | CRC | QIAm p | Infor med | 30 days | 40 | 13 (32%) | |
| Scholer et al., 2017 | I- O M IV | CRC | Signat era, bespok e | Infor med | 0, 8, 30 days, 3 Months | 27 | 6 (22%) | |
| Tie et al., 2016 (stage II) | п | Colo n | Roche | Infor med | 4-10 Weeks | 230 | 20 (8%) | Y |

| Tie et al., 2019 (colon) | III | Colo n | QIAm p | Infor med | 4-10 Weeks | 96 | 20 (20%) | Y |
|--|--------------|------------|-------------------------------|--------------|---------------|-----|-----------------|---|
| Tie et al., 2019 (rectum) | II- III | Rect al | QIAm p | Infor med | 4-10 Weeks | 159 | 19 (11%) | |
| Tie et al., 2021 | O M IV | CRC | QiAm p | Infor med | 4-10 Weeks | 54 | 12 (22%) | Y |
| Zhou et al., 2022 | II- III | Rect al | Signat era, bespok e | infor med | < 1 month | 89 | 6 (6%) | |

CRC = Colorectal Cancer; OM = Oligometastatic; NA = Not Available; * = Data was exclusively Used for Post-Adjuvant analysis

The data comprised of 3,568 patients. Of this population, 13.4% (477) were positive for ctDNA post-operatively. Likewise, 1,007 patients were assessed in the post-adjuvant setting.

Utilizing a random-effects model, analysis of our primary outcome, post-surgical ctDNA status, showed a statistically significant prognostic effect, pooled HR= 7.27 (95% CI 5.49-9.62, P < 0.0001). This indicates that the presence of a positive ctDNA results after surgery yields a poor prognosis. A forest plot of this data is shown in Figure 2. These data had moderate heterogeneity (I^2 =55%). Subgroup analyses were performed on these data, as shown in Table 2. There have been insufficient studies to stratify post-adjuvant ctDNA results for oligometastatic stage IV disease and tumor-agnostic methodologies. Among these analyses, all the pooled hazard ratios reached significance. Heterogeneity was improved when stratifying by the tumor-informed group. Similarly, heterogeneity improved when only oligometastatic stage IV was analyzed. Forest plots of tumor agnostic and tumor-informed ctDNA statuses are shown in Figure 3.

| | | | | Hazard Ratio | Hazard Ratio |
|---------------------------------------|------------------------------------|-----------|-------------------------|----------------------|--|
| Study or Subgroup | log[Hazard Ratio] | SE | Weight | IV, Random, 95% Cl | IV, Random, 95% Cl |
| Anandappa et al, 2021 | 2.3026 | 0.5657 | 3.8% | 10.00 [3.30, 30.31] | |
| Benhaim et al, 2021 | 1.1694 | 0.455 | 4.9% | 3.22 [1.32, 7.86] | |
| Bolhuis et al, 2021 | 1.1939 | 0.5502 | 4.0% | 3.30 [1.12, 9.70] | |
| Chen et al, 2021 | 2.3961 | 0.3707 | 5.8% | 10.98 [5.31, 22.71] | _ |
| Diehn et al, 2017 | 2.3321 | 0.7649 | 2.6% | 10.30 [2.30, 46.12] | |
| Gu et al, 2021 | 2.1041 | 0.7737 | 2.5% | 8.20 [1.80, 37.36] | · · · · · · · · · · · · · · · · · · · |
| Henriksen et al, 2021 | 2.3979 | 0.3354 | 6.3% | 11.00 [5.70, 21.23] | |
| Khakoo et al, 2020 | 3.6864 | 1.1735 | 1.3% | 39.90 [4.00, 397.99] | |
| Kotaka et al, 2022 | 2.7279 | 0.2939 | 6.8% | 15.30 [8.60, 27.22] | |
| Li et al, 2022 | 1.2768 | 0.3409 | 6.2% | 3.59 [1.84, 6.99] | _ |
| Loupakis et al, 2021 | 1.7579 | 0.2577 | 7.3% | 5.80 [3.50, 9.61] | |
| McDuff et al, 2021 | 2.4476 | 0.9076 | 2.0% | 11.56 [1.95, 68.47] | |
| Overman et al, 2017 | 1.1314 | 0.3065 | 6.7% | 3.10 [1.70, 5.65] | _ |
| Parikh et al, 2021 | 2.423 | 0.6228 | 3.4% | 11.28 [3.33, 38.23] | |
| Reinert et al, 2022 | 2.0281 | 0.4743 | 4.7% | 7.60 [3.00, 19.25] | |
| Scholer et al, 2017 | 3.6286 | 1.1192 | 1.4% | 37.66 [4.20, 337.71] | |
| Tie et al, 2016 | 2.5649 | 0.3459 | 6.2% | 13.00 [6.60, 25.61] | |
| Tie et al, 2019 (colon) | 1.335 | 0.2345 | 7.7% | 3.80 [2.40, 6.02] | |
| Tie et al, 2019 (rectum) | 2.5649 | 0.4389 | 5.0% | 13.00 [5.50, 30.73] | |
| Tie et al, 2021 | 1.8342 | 0.4522 | 4.9% | 6.26 [2.58, 15.19] | |
| Zhou et al, 2022 | 3.2308 | 1.4501 | 0.9% | 25.30 [1.47, 433.96] | · · · · · · · · · · · · · · · · · · · |
| Øgaard et al, 2022 | 1.5041 | 0.3889 | 5.6% | 4.50 [2.10, 9.64] | |
| Total (95% CI) | | | 100.0% | 7.27 [5.49, 9.62] | • |
| Heterogeneity: Tau ² = 0.2 | 21; Chi ² = 46.52, df = | 21 (P = 0 | .001); I ² = | 55% | |
| Test for overall effect: Z = | | | | | 0.01 0.1 1 10 100 Favours [ctDNA (-)] Favours [ctDNA (+)] |

Figure 2: Forest plot showing the pooled hazard ratio based on post-surgical ctDNA positive versus ctDNA negative status. The hazard ratio for each adverse event is represented by a square, and the horizontal lines crossing the squares represent the 95% confidence interval (CI).

 Table 2: Pooled Hazard Ratio for Subgroup Analyses based on Stage, Method of ctDNA analysis

| Subgroup | Pooled HR (CI) | Number of Studies |
|--------------------|--------------------------|-------------------|
| Post-surgical | 7.27 (95% CI 5.49-9.62) | 22 |
| Stage | | |
| I-III | 8.14 (95% CI 5.60-11.82) | 14 |
| IV oligometastatic | 4.83 (95% CI 3.64-6.39) | 8 |
| | | |

ctDNA Method

| Tumor-Informed | 8.66 (95% CI 6.38-11.75) | 17 |
|--------------------|---------------------------|----|
| Tumor-Agnostic | 3.76 (95% CI 2.58-5.48) | 5 |
| Post-Adjuvant | 10.59 (95% CI 5.59-20.06) | 7 |
| Stage | | |
| 1-111 | 10.60 (95% CI 4.21-26.69) | 5 |
| IV oligometastatic | NA | 2 |
| ctDNA Method | | |
| Tumor-Informed | 11.16 (95% CI 5.19-23.98) | 6 |
| Tumor-Agnostic | NA | 1 |




Figure 3B

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI | Hazard Ratio |
|-----------------------------------|------------------------------------|------------|-------------------------|------------------------------------|--|
| Benhaim et al, 2021 | 1.1694 | 0.455 | 17.8% | 3.22 [1.32, 7.86] | |
| Bolhuis et al, 2021 | 1.1939 | 0.5605 | 11.7% | 3.30 [1.10, 9.90] | i — |
| Overman et al, 2017 | 1.1314 | 0.3065 | 39.3% | 3.10 [1.70, 5.65] | |
| Parikh et al, 2021 | 2.423 | 0.7364 | 6.8% | 11.28 [2.66, 47.77] | i ——— |
| Øgaard et al, 2022 | 1.5041 | 0.3889 | 24.4% | 4.50 [2.10, 9.64] | i – |
| Total (95% CI) | | | 100.0% | 3.76 [2.58, 5.48] | • • |
| Heterogeneity: Tau ² = | 0.00; Chi ² = 3.01, df: | = 4 (P = 0 | 0.56); I ² = | 0% | |
| Test for overall effect: | | - | | | 0.01 0.1 1 10 100 Favours [ctDNA (-)] Favours [ctDNA (+)] |

Figure 3: Forest plot showing the pooled hazard ratio based on ctDNA method (A) postsurgical ctDNA positive versus ctDNA negative status via the tumor-informed method. (B) post-surgical ctDNA positive versus ctDNA negative status via tumor agnostic method. The hazard ratio for each adverse event is represented by a square, and the horizontal lines crossing the squares represent the 95% confidence interval (CI).

Similarly, a random-effects model was used to calculate the pooled HR for ctDNA status in the post-adjuvant chemotherapy setting, which also yielded a statistically significant result that positive ctDNA implies a higher risk of recurrence, pooled HR = 10.59 (95% CI 5.59-20.06) (Figure 4). Unfortunately, a meta-analysis could only be performed on stages I-III and tumor-informed methodology in the post-adjuvant setting owing to the smaller number of studies.




Figure 4: Forest plot showing the pooled hazard ratio based on the ctDNA method based on post-adjuvant ctDNA positive versus ctDNA negative status. The hazard ratio for each adverse event is represented by a square, and the horizontal lines crossing the squares represent the 95% confidence interval (CI).

Discussion:

Our study demonstrated that patients with ctDNA-positive status after curative intent surgery was significantly associated with low RFS, pooled HR= 7.27 (95% CI 5.49-9.62, p < 0.0001). This indicates that patients with positive ctDNA following curative-intent surgery have a poorer prognosis than ctDNA-negative patients. Based on these results, ctDNA analysis can reliably identify patients at a higher risk of recurrence and those who can benefit from adjuvant systemic treatments. This could spare patients from unnecessary or inappropriate toxic treatments. Therefore, ctDNA analysis could also be used as a predictive marker. A phase II/III study, NRG-GI005 (COBRA), is currently testing whether ctDNA can be a predictive biomarker for adjuvant chemotherapy benefit in patients with resected Stage II colon cancer.²¹

After practicing for decades with no reliable minimally invasive marker, it is practice changing to now have post-operative ctDNA analysis to help guide our decisions regarding adjuvant therapy. Our study is the largest meta-analysis to explore the role of ctDNA assay. A smaller meta-analysis of 7 studies with data prior to 2019 included 424 patients and showed a statistically significant association between post-surgical ctDNA and RFS.²² The current prospective studies with ctDNA have a small number of patients and do not reflect the true value of ctDNA in MRD monitoring.²³ Our meta-analyses included 23 studies with 3,568 patients ^{16,18,19,24-32}. This speaks to the rapidly expanding number of studies on the topic. Synthesizing an emerging abundance of robust data is essential.

We performed subgroup analyses of patients based on the CRC stage. Patients with stage I-III CRC are eight times more likely to recur with positive ctDNA results than ctDNA negative patients. This provides an indicator for patients who may benefit from further adjuvant treatment to prevent recurrence. Further studies on this topic are ongoing. CIRCULATE-Japan, which encompasses three clinical trials, is currently examining the clinical benefits of ctDNA analysis and adjuvant treatment in patients with resectable CRC.^{33,34}

Our analysis also showed that patients who had positive ctDNA after receiving adjuvant chemotherapy had a poorer prognosis with lower RFS than ctDNA-negative comparators (HR 10.59, 95% CI 5.59-20.06). Post-adjuvant ctDNA levels could be used to determine the risk of

recurrence and the need for further close surveillance.^{35,36} For example, nearly half of the patients with stage IV CRC with liver oligometastases recur after curative intent surgery. Reinert and colleagues studied these patients with serial ctDNA studies in addition to routine surveillance imaging.³⁷ The study showed that ctDNA detected recurrence with a median time of 2.5 months (p< .0001) prior to routine surveillance imaging, especially in those with indeterminate CT findings. This indicates that ctDNA can be used as a surveillance tool to assess recurrence. In a study of 138 patients with metastatic gastrointestinal cancer, Parikh et al. found that serial ctDNA monitoring could predict the response to systemic treatment. ³⁸Currently NRG-GI008 trial is recruiting patients with Stage III and high-risk Stage II colon cancer to determine which patients benefit from adjuvant chemotherapy based on the ctDNA results.³⁹

We also explored the role of different ctDNA analysis methods on prognostications, as previous studies have shown that tumor-informed methods are more sensitive and specific compared to tumor-agnostic methods. We performed a subgroup analysis of ctDNA analysis methods in the post-surgical setting. This demonstrated that ctDNA positivity using tumor-informed and tumor-agnostic methods was associated with low RFS with pooled hazard ratios of 8.66 (95% CI 6.38-11.75) and HR=3.76 (95% CI 2.58-5.48), respectively.^{40,41} While this data indicates better prognostication for tumor-informed methodologies in line with previously published information, and the studies included did not include head-to-head analysis, so conclusive arguments are difficult to make from this data. However, this is consistent with previously published results, which showed that studies that used tumor-informed assays showed higher rates of recurrences than those that used tumor-agnostic assays.

Monitoring ctDNA levels in the blood has been shown to accurately detect MRD and aid in measuring the therapeutic effects after curative treatment. While ctDNA is not yet the standard of care in clinical practice for CRC patients, studies are ongoing to define the appropriate way to use it as a tool in the clinic. ^{42–44} In 2022, a phase two randomized trial, Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy (DYNAMIC), showed non-inferiority in 2-year recurrence-free survival between the standard management group and ctDNA-guided management in stage II CRC patients after curative intent surgery (93.5% vs. 92.4%, 95% CI [-4.1 to 6.2], non-inferiority margin, -8.5 percentage points). ⁴⁵ Our study builds on this issue. To our knowledge, this is the largest meta-analysis to confirm the prognostic and predictive power of ctDNA levels in the post-operative and post-ACT settings.

Limitations

Abstracts with insufficient or imprecise data were excluded. Studies that included Stage 0 CRC were omitted if they lacked subgroup analysis excluding this population. The sensitivity and specificity of the ctDNA methods are different. We attempted to overcome this by performing subgroup analysis of tumor-naive vs. tumor-informed techniques. Multiple abstracts were published on the same population at different time points during follow-up, so we eliminated the duplicates by reviewing all abstracts and manuscripts in detail and included only the most recent abstract or manuscripts with the greatest patient population. As this is a new technique, many studies have lacked extensive follow-up. There are also limited studies for certain populations that prevent meta-analyses from being performed. Additionally, Oligometastatic CRC patients were found to have a lower hazard ratio than earlier-stage cancers, which could be secondary to the limited number of studies in this setting.

Conclusion:

Our study is the largest and most up-to-date meta-analysis of studying the effect of ctDNA status in both post-curative intent surgery and post-ACT in CRC. Our study validated the role of ctDNA analysis in stage I to oligometastatic stage IV CRC. Our analysis emphasizes that post-operative ctDNA is a strong prognostic marker of RFS. Based on our results, ctDNA can be a significant and independent predictor of RFS. This real-time assessment of treatment benefits can be used as a surrogate endpoint for the development of novel drugs. Few ctDNA-based clinical trials are ongoing internationally to confirm the clinical utility of ctDNA in colorectal cancer. Further randomized clinical trials, in which ctDNA results are used to inform patient management, are required to assess the clinical utility of ctDNA-guided approaches for colorectal cancer management and surveillance.

References:

1. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and latestage human malignancies. *Sci Transl Med*. 2014;6(224):224ra24. doi:10.1126/scitranslmed.3007094

2. Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. *Nature*. 2019;570(7761):385-389. doi:10.1038/s41586-019-1272-6

3. Corcoran RB, Chabner BA. Application of Cell-free DNA Analysis to Cancer Treatment. *New England Journal of Medicine*. 2018;379(18):1754-1765. doi:10.1056/NEJMra1706174

4. Llavero NT, Gimeno-Valiente F, Gambardella V, et al. Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype. *Annals of Oncology*. 2019;30:v198. doi:10.1093/annonc/mdz246

5. Merker JD, Oxnard GR, Compton C, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. *Archives of Pathology & Laboratory Medicine*. 2018;142(10):1242-1253. doi:10.5858/arpa.2018-0901-SA

6. Gorgannezhad L, Umer M, Islam MN, Nguyen NT, Shiddiky MJA. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. *Lab Chip*. 2018;18(8):1174-1196. doi:10.1039/C8LC00100F

7. Liquid biopsies come of age: towards implementation of circulating tumour DNA | Nature Reviews Cancer. Accessed October 30, 2022. https://www.nature.com/articles/nrc.2017.7

8. Peng Y, Mei W, Ma K, Zeng C. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. *Front Oncol*. 2021;11:763790. doi:10.3389/fonc.2021.763790

9. Parikh AR, Corcoran RB. Plasma-only ctDNA-Guided MRD Detection in Patients with CRC— Response. *Clinical Cancer Research*. 2021;27(23):6614-6615. doi:10.1158/1078-0432.CCR-21-3306 10. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant Treatment of Colorectal Cancer. *CA: A Cancer Journal for Clinicians*. 2007;57(3):168-185. doi:10.3322/canjclin.57.3.168

11. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. *JAMA*. 1988;259(24):3571-3578.

12. Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up⁺. *Annals of Oncology*. 2020;31(10):1291-1305. doi:10.1016/j.annonc.2020.06.022

13. Morris EJA, Maughan NJ, Forman D, Quirke P. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. *Gut*. 2007;56(10):1419-1425. doi:10.1136/gut.2006.116830

14. Kannarkatt J, Joseph J, Kurniali PC, Al-Janadi A, Hrinczenko B. Adjuvant Chemotherapy for Stage Il Colon Cancer: A Clinical Dilemma. *J Oncol Pract*. 2017;13(4):233-241. doi:10.1200/JOP.2016.017210

15. Chakrabarti S, Peterson CY, Sriram D, Mahipal A. Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. *World Journal of Gastrointestinal Oncology*. 2020;12(8):808-832. doi:10.4251/wjgo.v12.i8.808

16. Tie J, Wang Y, Springer S, et al. Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM). *JCO*. 2016;34(15_suppl):e15131-e15131. doi:10.1200/JCO.2016.34.15_suppl.e15131

17. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices - PMC. Accessed October 30, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390824/

18. Henriksen TVV, Tarazona N, Frydendahl A, et al. Serial circulating tumor DNA analysis to assess recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in stage III colorectal cancer patients. *JCO*. 2021;39(15_suppl):3540-3540. doi:10.1200/JCO.2021.39.15_suppl.3540

19. Henriksen TV, Tarazona N, Frydendahl A, et al. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. *Clinical Cancer Research*. 2022;28(3):507-517. doi:10.1158/1078-0432.CCR-21-2404

20. Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses. *Stat Med*. 2010;29(12):1282-1297. doi:10.1002/sim.3602

21. Morris VK, Yothers G, Kopetz S, et al. NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer. *JCO*. 2020;38(4_suppl):TPS261-TPS261. doi:10.1200/JCO.2020.38.4_suppl.TPS261

22. Wang R, Zhao A, Cao N, Li Z, Zhang G, Liu F. The value of circulation tumor DNA in predicting post-operative recurrence of colorectal cancer: a meta-analysis. *Int J Colorectal Dis.* 2020;35(8):1463-1475. doi:10.1007/s00384-020-03667-y

23. Tie J, Cohen JD, Lo SN, et al. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. *International Journal of Cancer*. 2021;148(4):1014-1026. doi:10.1002/ijc.33312

24. Zhou J, Wang C, Lin G, et al. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study. *Clinical Cancer Research*. 2021;27(1):301-310. doi:10.1158/1078-0432.CCR-20-2299

25. Tarazona N, Gimeno-Valiente F, Gambardella V, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. *Annals of Oncology*. 2019;30(11):1804-1812. doi:10.1093/annonc/mdz390

26. Schøler LV, Reinert T, Ørntoft MBW, et al. Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. *Clinical Cancer Research*. 2017;23(18):5437-5445. doi:10.1158/1078-0432.CCR-17-0510

27. McDuff SGR, Hardiman KM, Ulintz PJ, et al. Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. *JCO Precision Oncology*. 2021;(5):123-132. doi:10.1200/PO.20.00220

28. Loupakis F, Sharma S, Derouazi M, et al. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. *JCO Precision Oncology*. 2021;(5):1166-1177. doi:10.1200/PO.21.00101

29. Liu W, Li Y, Tang Y, et al. Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA. *eBioMedicine*. 2022;78. doi:10.1016/j.ebiom.2022.103945

30. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer | Clinical Cancer Research | American Association for Cancer Research. Accessed November 2, 2022.

https://aacrjournals.org/clincancerres/article/26/1/183/82432/MRI-Tumor-Regression-Grade-and-Circulating-Tumor

31. Anandappa G, Starling N, Begum R, et al. Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC). *JCO*. 2021;39(3_suppl):102-102. doi:10.1200/JCO.2021.39.3_suppl.102

32. Benhaim L, Bouché O, Normand C, et al. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). *European Journal of Cancer*. 2021;159:24-33. doi:10.1016/j.ejca.2021.09.004

33. Taniguchi H, Nakamura Y, Kotani D, et al. CIRCULATE-Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. *Cancer Science*. 2021;112(7):2915-2920. doi:10.1111/cas.14926

34. Kotaka M, Shirasu H, Watanabe J, et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. *JCO*. 2022;40(4_suppl):9-9. doi:10.1200/JCO.2022.40.4_suppl.009

35. Koulouris A, Tsagkaris C, Messaritakis I, et al. Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies. *Cancers (Basel)*. 2021;13(14):3522. doi:10.3390/cancers13143522

36. Tie J, Cohen JD, Lahouel K, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. *New England Journal of Medicine*. 2022;386(24):2261-2272. doi:10.1056/NEJMoa2200075

37. Reinert T, Petersen LMS, Henriksen TV, et al. Circulating tumor DNA for prognosis assessment and post-operative management after curative-intent resection of colorectal liver metastases. *Int J Cancer*. 2022;150(9):1537-1548. doi:10.1002/ijc.33924

38. Parikh AR, Mojtahed A, Schneider JL, et al. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. *Clinical Cancer Research*. 2020;26(8):1877-1885. doi:10.1158/1078-0432.CCR-19-3467

39. NRG-GI008: CIRCULATE-US Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease. Accessed November 4, 2022. https://www.nrgoncology.org/CIRCULATE-US

40. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. *Clinical Cancer Research*. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410

41. Øgaard N, Reinert T, Henriksen TV, et al. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study. *European Journal of Cancer*. 2022;163:163-176. doi:10.1016/j.ejca.2021.12.026

42. Masfarré L, Vidal J, Fernández-Rodríguez C, Montagut C. ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC). *Cancers (Basel)*. 2021;13(12):2869. doi:10.3390/cancers13122869

43. Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. *Nat Rev Clin Oncol*. 2020;17(12):757-770. doi:10.1038/s41571-020-0392-0

44. Malla M, Loree JM, Kasi PM, Parikh AR. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. *JCO*. 2022;40(24):2846-2857. doi:10.1200/JCO.21.02615

45. Tie J, Cohen JD, Lahouel K, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. *New England Journal of Medicine*. 2022;386(24):2261-2272. doi:10.1056/NEJMoa2200075